Reduction of erythrocyte sedimentation rate

Information

  • Patent Grant
  • 12089588
  • Patent Number
    12,089,588
  • Date Filed
    Thursday, August 12, 2021
    3 years ago
  • Date Issued
    Tuesday, September 17, 2024
    2 months ago
Abstract
The present invention relates to reduction of erythrocyte sedimentation rate in a blood sample. In particular, formulations, compositions, articles of manufacture, kits and methods for reduced erythrocyte sedimentation rate in a blood sample are provided.
Description
BACKGROUND OF THE INVENTION

There exists a need for improved formulations and methods for reducing the rate of blood sedimentation for a time sufficient for storage, transport, and shipping for research, diagnostic and therapeutic purposes.


The present invention relates generally to the reduction of sedimentation rate of one or more erythrocytes in a blood sample. In particular, the invention relates to formulations, compositions, articles of manufacture, kits and methods for the reduction of erythrocyte sedimentation rate in a blood sample.


SUMMARY OF THE INVENTION

Described herein, in some embodiments, are in vitro methods for reducing the erythrocyte sedimentation rate in a blood sample, comprising: combining a sample of blood with an amount of a formulation comprising sucralose, wherein the amount is sufficient to produce a treated blood sample having a sucralose concentration of at least about 5 mM sucralose, thereby reducing the erythrocyte sedimentation rate as compared to erythrocyte sedimentation rate in an untreated blood sample. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 100 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 10 mM sucralose to about 100 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 20 mM sucralose to about 100 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 24 mM sucralose to about 100 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 15 mM sucralose to about 50 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 50 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 40 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 10 mM sucralose to about 35 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 10 mM sucralose to about 30 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 25 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose up to but not including 25 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 20 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 15 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 10 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 24 mM. In some embodiments, the treated blood sample has a sucralose concentration of about 25 mM. In some embodiments, erythrocyte sedimentation rate is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the erythrocyte sedimentation rate of the untreated blood sample. In some embodiments, the formulation is in the form of a powder, a solid, a lyophilized form, a solution, or an aqueous solution. In some embodiments, the formulation is a powder. In some embodiments, the formulation is a solid. In some embodiments, the formulation is lyophilized. In some embodiments, the formulation is a solution. In some embodiments, the solution is an aqueous solution. In some embodiments, the formulation consists of sucralose. In some embodiments, the formulation further comprises an anticoagulant. In some embodiments, the anticoagulant is selected from the group consisting of acid citrate dextrose solution (ACD), sodium heparin, sodium fluoride, lithium heparin, tri-potassium ethylenediaminetetraacetic acid (K3EDTA), di-potassium ethylenediaminetetraacetic acid (K2EDTA), hirudin, and sodium polyanethol sulfonate (SPS). In some embodiments, the anticoagulant is acid citrate dextrose solution (ACD). In some embodiments, the anticoagulant is sodium heparin. In some embodiments, the anticoagulant is sodium fluoride. In some embodiments, the anticoagulant is lithium heparin. In some embodiments, the anticoagulant is tri-potassium ethylenediaminetetraacetic acid (K3EDTA). In some embodiments, the anticoagulant is di-potassium ethylenediaminetetraacetic acid (K2EDTA). In some embodiments, the anticoagulant is hirudin. In some embodiments, the anticoagulant is sodium polyanethol sulfonate (SPS). In some embodiments, the formulation is contained within a blood collection tube, and the combining step occurs within the blood collection tube. In some embodiments, the blood collection tube is an evacuated blood collection tube. In some embodiments, the blood is collected from a subject. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.


Described herein, in some embodiments, are in vitro methods for maintaining one or more erythrocytes in suspension in a blood sample, comprising: combining a sample of blood with an amount of a formulation comprising sucralose, wherein the amount is sufficient to produce a treated blood sample having a sucralose concentration of at least about 5 mM sucralose, thereby maintaining the one or more erythrocytes in suspension for a period of at least 30 minutes as compared to an untreated blood sample. In some embodiments, the one or more erythrocytes remain in suspension for a period of at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, at least 90 minutes, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 7 hours, at least 8 hours, at least 10 hours, at least 12 hours, at least 24 hours or at least 48 hours. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 100 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 10 mM sucralose to about 100 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 20 mM sucralose to about 100 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 24 mM sucralose to about 100 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 15 mM sucralose to about 50 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 50 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 40 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 10 mM sucralose to about 35 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 10 mM sucralose to about 30 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 25 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose up to but not including 25 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 20 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 15 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 10 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 24 mM. In some embodiments, the treated blood sample has a sucralose concentration of about 25 mM. In some embodiments, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the one or more erythrocytes remain in suspension in the treated blood sample as compared to the untreated blood sample. In some embodiments, the formulation is a powder. In some embodiments, the formulation is a solid. In some embodiments, the formulation is lyophilized. In some embodiments, the formulation is a solution. In some embodiments, the solution is an aqueous solution. In some embodiments, the formulation consists of sucralose. In some embodiments, the formulation further comprises an anticoagulant. In some embodiments, the anticoagulant is selected from the group consisting of acid citrate dextrose solution (ACD), sodium heparin, sodium fluoride, lithium heparin, tri-potassium ethylenediaminetetraacetic acid (K3EDTA), di-potassium ethylenediaminetetraacetic acid (K2EDTA), hirudin, and sodium polyanethol sulfonate (SPS). In some embodiments, the anticoagulant is acid citrate dextrose solution (ACD). In some embodiments, the anticoagulant is sodium heparin. In some embodiments, the anticoagulant is sodium fluoride. In some embodiments, the anticoagulant is lithium heparin. In some embodiments, the anticoagulant is tri-potassium ethylenediaminetetraacetic acid (K3EDTA). In some embodiments, the anticoagulant is di-potassium ethylenediaminetetraacetic acid (K2EDTA). In some embodiments, the anticoagulant is hirudin. In some embodiments, the anticoagulant is sodium polyanethol sulfonate (SPS). In some embodiments, the formulation is contained within a blood collection tube, and the combining step occurs within the blood collection tube. In some embodiments, the blood collection tube is an evacuated blood collection tube. In some embodiments, the blood sample is collected from a subject. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.


Described herein, in some embodiments, are compositions comprising a blood sample and sucralose, wherein the sucralose is at a concentration of about 5 mM sucralose up to about 100 mM sucralose. In some embodiments, the sucralose is at a concentration of about 10 mM sucralose to about 100 mM sucralose. In some embodiments, the sucralose is at a concentration of about 20 mM sucralose to about 100 mM sucralose. In some embodiments, the sucralose is at a concentration of about 24 mM sucralose to about 100 mM sucralose. In some embodiments, the sucralose is at a concentration of about 15 mM sucralose to about 50 mM sucralose. In some embodiments, the sucralose is at a concentration of about 5 mM sucralose to about 50 mM sucralose. In some embodiments, the sucralose is at a concentration of about 5 mM sucralose to about 40 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 10 mM sucralose to about 35 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 10 mM sucralose to about 30 mM sucralose. In some embodiments, the sucralose is at a concentration of about 5 mM sucralose up to but not including 25 mM sucralose. In some embodiments, the sucralose is at a concentration of about 5 mM sucralose to about 20 mM sucralose. In some embodiments, the sucralose is at a concentration of about 5 mM sucralose to about 15 mM sucralose. In some embodiments, the sucralose is at a concentration of about 5 mM sucralose to about 10 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 24 mM. In some embodiments, the treated blood sample has a sucralose concentration of about 25 mM. In some embodiments, the compositions further comprise an anticoagulant. In some embodiments, the anticoagulant is selected from the group consisting of acid citrate dextrose solution (ACD), sodium heparin, sodium fluoride, lithium heparin, tri-potassium ethylenediaminetetraacetic acid (K3EDTA), di-potassium ethylenediaminetetraacetic acid (K2EDTA), hirudin, and sodium polyanethol sulfonate (SPS). In some embodiments, the anticoagulant is acid citrate dextrose solution (ACD). In some embodiments, the anticoagulant is sodium heparin. In some embodiments, the anticoagulant is sodium fluoride. In some embodiments, the anticoagulant is lithium heparin. In some embodiments, the anticoagulant is tri-potassium ethylenediaminetetraacetic acid (K3EDTA). In some embodiments, the anticoagulant is di-potassium ethylenediaminetetraacetic acid (K2EDTA). In some embodiments, the anticoagulant is hirudin. In some embodiments, the anticoagulant is sodium polyanethol sulfonate (SPS). In some embodiments, the composition is contained within a blood collection tube. In some embodiments, the blood collection tube is an evacuated blood collection tube. In some embodiments, the blood is collected from a subject. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.


Described herein, in some embodiments, are articles of manufacture, comprising sucralose contained within a blood collection tube, wherein the sucralose is in a quantity sufficient to produce a final concentration of about 5 mM sucralose to about 100 mM sucralose in the blood sample. In some embodiments, the sucralose is in a quantity sufficient to produce a final concentration of about 10 mM sucralose to about 100 mM sucralose. In some embodiments, the sucralose is in a quantity sufficient to produce a final concentration of about 20 mM sucralose to about 100 mM sucralose. In some embodiments, the sucralose is in a quantity sufficient to produce a final concentration of about 24 mM sucralose to about 100 mM sucralose. In some embodiments, the sucralose is in a quantity sufficient to produce a final concentration of about 15 mM sucralose to about 50 mM sucralose. In some embodiments, the sucralose is in a quantity sufficient to produce a final concentration of about 5 mM sucralose to about 50 mM sucralose in the blood sample. In some embodiments, the sucralose is in a quantity sufficient to produce a final concentration of about 5 mM sucralose to about 40 mM sucralose in the blood sample. In some embodiments, the treated blood sample has a sucralose concentration of about 10 mM sucralose to about 35 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 10 mM sucralose to about 30 mM sucralose. In some embodiments, the sucralose is in a quantity sufficient to produce a final concentration of about 5 mM sucralose to up to but not including 25 mM sucralose in the blood sample. In some embodiments, the sucralose is in a quantity sufficient to produce a final concentration of about 5 mM sucralose to about 20 mM sucralose in the blood sample. In some embodiments, the sucralose is in a quantity sufficient to produce a final concentration of about 5 mM sucralose to about 15 mM sucralose in the blood sample. In some embodiments, the sucralose is in a quantity sufficient to produce a final concentration of about 5 mM sucralose to about 10 mM sucralose in the blood sample. In some embodiments, the treated blood sample has a sucralose concentration of about 24 mM. In some embodiments, the treated blood sample has a sucralose concentration of about 25 mM. In some embodiments, the sucralose is a powder. In some embodiments, the sucralose is a solid. In some embodiments, the sucralose is lyophilized. In some embodiments, the sucralose is in solution. In some embodiments, the sucralose solution is an aqueous solution. In some embodiments, the blood collection tube is an evacuated blood collection tube. In some embodiments, the articles of manufacture further comprise an anticoagulant. In some embodiments, the anticoagulant is selected from the group consisting of acid citrate dextrose solution (ACD), sodium heparin, sodium fluoride, lithium heparin, tri-potassium ethylenediaminetetraacetic acid (K3EDTA), di-potassium ethylenediaminetetraacetic acid (K2EDTA), hirudin, and sodium polyanethol sulfonate (SPS). In some embodiments, the anticoagulant is acid citrate dextrose solution (ACD). In some embodiments, the anticoagulant is sodium heparin. In some embodiments, the anticoagulant is sodium fluoride. In some embodiments, the anticoagulant is lithium heparin. In some embodiments, the anticoagulant is tri-potassium ethylenediaminetetraacetic acid (K3EDTA). In some embodiments, the anticoagulant is di-potassium ethylenediaminetetraacetic acid (K2EDTA). In some embodiments, the anticoagulant is hirudin. In some embodiments, the anticoagulant is sodium polyanethol sulfonate (SPS).


Described herein, in some embodiments, are kits, comprising an article of manufacture provided herein, and a package insert.


INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.





BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:



FIGS. 1A-1C illustrate reduction of erythrocyte sedimentation rate in whole blood following addition of 0.5 M sucralose, PBS, or saline. Storage was for 0 hours (FIG. 1A), 6 hours (FIG. 1B), and 24 hours (FIG. 1C). NF=no formulation control.



FIG. 2 illustrates sedimentation rate of erythrocytes in whole blood following addition of the indicated solution of sucralose, the indicated saccharide, PBS, or saline. Storage was for 1 hour (upper panel) and 6 hours (center panel). Lack of hemolysis from the reduction of sedimentation rate is illustrated in the bottom panel by centrifugation after 7 hours of storage.



FIG. 3 illustrates sedimentation rate of erythrocytes following addition of sucralose in powder form to the indicated final concentration. Storage of samples was for 1 hour (upper panel) and 6 hours (lower panel). NF=no formulation control.



FIG. 4 illustrates the effect of different anticoagulants on sedimentation rate of erythrocytes collected from whole blood. Samples were collected into blood collection tubes containing the indicated anticoagulant. Storage of samples following addition of a solution of 0.5 M sucralose or PBS was for 2 hours (upper panel) and 8 hours (lower panel). NF=no formulation control.



FIG. 5 illustrates the effect of a solution of 0.5 M sucralose on sedimentation rate of erythrocytes in whole blood compared to PBS, the indicated polyols, and the indicated halogenated polyols. Storage of samples was for 2 hours. NF=no formulation control.





DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to formulations, compositions, articles of manufacture, kits, and methods for reduction of sedimentation rate of one or more erythrocytes in a blood sample.


In some embodiments, the formulations, methods, and compositions provided herein provide for reduced sedimentation rate and thus storage of the one or more erythrocytes in a blood sample at the injection site of a microfluidic device. Reduction of sedimentation rate of one or more erythrocytes in a blood sample allows for the slow injection of one or more erythrocytes into the microinjection device without the need for prior sample mixing.


Erythrocyte sedimentation rate is used as a parameter for prognosis of diseases such as multiple myeloma, temporal arteritis, polymyalgia rheumatica, systemic lupus erythematosus, and rheumatoid arthritis. Thus, in some embodiments, the formulations, methods, and compositions for reduction of erythrocyte sedimentation rate in a blood sample provided herein may benefit patients with diseases that correlate with an increased rate of erythrocyte sedimentation.


Definitions

As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, references to “the method” includes one or more methods, and/or steps of the type described herein which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.


“About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20%, or ±10%, or ±5%, or even ±1% from the specified value, as such variations are appropriate for the disclosed compositions or to perform the disclosed methods.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.


The term “ambient temperature” as used herein refers to common indoor room temperatures. In some embodiments, ambient temperature is 15 to 32° C. In some embodiments, ambient temperature is 20 to 27° C.


As used herein, the terms “reduced sedimentation rate,” “reducing sedimentation rate,” and “reduction of sedimentation rate,” refer to the ability of a material to decrease the sedimentation rate of erythrocytes in a blood sample. In some embodiments, erythrocyte sedimentation rate is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the erythrocyte sedimentation rate of the untreated blood sample. In some embodiments, reduction of sedimentation rate refers to the ability of a material to prevent one or more erythrocytes in a blood sample from settling out of suspension due to the force of gravity. In some embodiments, one or more erythrocytes are maintained in suspension for at least 30 minutes. In some embodiments, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of one or more erythrocytes remain in suspension in the treated blood sample as compared to the untreated blood sample. In some embodiments, one or more erythrocytes remain in suspension for at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, at least 90 minutes, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 7 hours, at least 8 hours, at least 10 hours, at least 12 hours, at least 24 hours or at least 48 hours.


Formulation Reagents


pH Buffers


According to certain embodiments, the herein described formulations and compositions for the reduction of sedimentation rate of one or more erythrocytes in a blood sample include one or more pH buffers. In some embodiments, the pH buffer is any of a large number of compounds known in the art for their ability to resist changes in the pH of a solution, such as in an aqueous solution in which the pH buffer is present. Selection of one or more particular pH buffers for inclusion in a stable storage composition may be done based on the present disclosure and according to routine practices in the art, and may be influenced by a variety of factors including the pH that is desired to be maintained, the nature of the biological sample, the solvent conditions to be employed, the other components of the formulation to be used, and other criteria. For example, typically a pH buffer is employed at a pH that is within about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 pH unit of a proton dissociation constant (pKa) that is a characteristic of the buffer.


Non-limiting examples of pH buffers include citric acid, tartaric acid, malic acid, sulfosalicylic acid, sulfoisophthalic acid, oxalic acid, borate, CAPS (3-(cyclohexylamino)-1-propanesulfonic acid), CAPSO (3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid), EPPS (4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid), HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), MOPSO (3-morpholino-2-hydroxypropanesulfonic acid), PIPES (1,4-piperazinediethanesulfonic acid), TAPS (N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid), TAPSO (2-hydroxy-3-[tris(hydroxymethyl)methylamino]-1-propanesulfonic acid), TES (N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid), bicine (N,N-bis(2-hydroxyethyl)glycine), tricine (N-[tris(hydroxymethyl)methyl]glycine), tris (tris(hydroxymethyl)aminomethane) and bis-tris (2-[bis(2-hydroxyethy)amino]-2-(hydroxymethyl)-1,3-propanediol). In some embodiments, the formulations have a pH of about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, or 9.0.


Disaccharide Derivatives


In certain embodiments, the formulations or compositions for reduction of sedimentation rate of erythrocytes in a blood sample include at least one halogenated disaccharide derivative. In some embodiments, the halogenated disaccharide derivative is a di- or tri-chlorinated disaccharide. In some embodiments, such di- or tri-chlorinated disaccharides unexpectedly are capable of reducing sedimentation rate of erythrocytes in a blood sample either alone or in the presence of only a buffer. Halogenated disaccharide derivatives are known, e.g., see US Patent Publication No. 2014/0065062, and include sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside), trichloronated maltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside, and 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside. Selection of one or more particular halogenated disaccharide derivative for inclusion in a formulation or composition for reduction of sedimentation rate of erythrocytes in a blood sample may be done based on the present disclosure and according to routine practices in the art, and may be influenced by a variety of factors including other formulation components.


In some embodiments, the halogenated disaccharide derivative is sucralose. In some embodiments, the sucralose is provided in solution as a formulation for mixing with a blood sample. In some embodiments, the solution is an aqueous solution. In some embodiments, the sucralose is present in the formulation at about 5-500 mM. In some embodiments, the sucralose is present in the formulation at about 10-500 mM. In some embodiments, the sucralose is present in the formulation at about 50-500 mM. In some embodiments, the sucralose is present in the formulation at about 100-500 mM. In some embodiments, the sucralose is present in the formulation at about 250-500 mM. In some embodiments, the sucralose is present in the formulation at about 5-630 mM. In some embodiments, the sucralose is present in the formulation at about 5-750 mM. In some embodiments, the sucralose is present in the formulation at about 10-750 mM. In some embodiments, the sucralose is present in the formulation at about 50-750 mM. In some embodiments, the sucralose is present in the formulation at about 100-750 mM. In some embodiments, the sucralose is present in the formulation at about 250-750 mM. In some embodiments, the formulation is a mixture of water and sucralose.


In some embodiments, the formulation is provided in an amount sufficient to produce a final concentration of sucralose of about 5 to about 25 mM, when mixed with a blood sample. In some embodiments, the sucralose is present in the formulation at about 500 mM and is mixed with a blood sample at a ratio of 1:20 (v/v) (formulation to blood). In some embodiments, the sucralose is present in the formulation at greater than 25 mM up to 100 mM. In some embodiments, the sucralose is present in the formulation at about 13-24 mM. In some embodiments, the sucralose is provided in powder form as a formulation for mixing with a blood sample. In some embodiments, the sucralose powder is provided in an amount sufficient to produce a final concentration of sucralose of about 5 to about 25 mM, when mixed with a blood sample.


In some embodiments, the sucralose is present at a final concentration of about 5-100 mM, when mixed with a blood sample. In some embodiments, the sucralose is present at a final concentration of about 5-50 mM, when mixed with a blood sample. In some embodiments, the sucralose is present at a final concentration of about 5-25 mM, when mixed with a blood sample. In some embodiments, the sucralose is present at a final concentration of about 5 up to but not including 25 mM, when mixed with a blood sample. In some embodiments, the sucralose is present at a final concentration of about 5-20 mM, when mixed with a blood sample. In some embodiments, the sucralose is present at a final concentration of about 5-15 mM, when mixed with a blood sample. In some embodiments, the sucralose is present at a final concentration of about 10-20 mM, when mixed with a blood sample. In some embodiments, the sucralose is present at a final concentration of about 10-15 mM, when mixed with a blood sample. In some embodiments, the sucralose is present at a final concentration of about 5-10 mM, when mixed with a blood sample. In some embodiments, the sucralose and is present at a final concentration of about 25 mM, when mixed with a blood sample.


Anticoagulants


In some embodiments, an anticoagulant is included in the presently described formulations and compositions. Such anticoagulants are known in the art. Exemplary anticoagulants include acid citrate dextrose solution (ACD), ethylenediaminetetraacetic acid (EDTA), tri-potassium ethylenediaminetetraacetic acid (K3EDTA), di-potassium ethylenediaminetetraacetic acid (K2EDTA), heparin, sodium heparin, sodium fluoride, lithium heparin, sodium citrate, hirudin, and sodium polyanethol sulfonate (SPS). In some embodiments, the anticoagulant is contained within a blood collection tube.


Exemplary Formulations for Reduction of Erythrocyte Sedimentation Rate in a Blood Sample

Described herein, in some embodiments, are formulations comprising sucralose. In some embodiments, the sucralose is present at a final concentration of about 5 mM sucralose to about 50 mM sucralose, when mixed with a blood sample. In some embodiments, the sucralose is present at a final concentration of about 5 mM sucralose to about 25 mM sucralose, when mixed with a blood sample. In some embodiments, the sucralose is present at a final concentration of about 5 mM sucralose up to, but not including, 25 mM sucralose. In some embodiments, the sucralose is present at a final concentration of about 5 mM sucralose to about 20 mM sucralose. In some embodiments, the sucralose is present at a final concentration of about 5 mM sucralose to about 15 mM sucralose. In some embodiments, the sucralose is present at a final concentration of about 5 mM sucralose to about 10 mM sucralose. In some embodiments, the sucralose is present as a solution. In some embodiments, the solution is an aqueous solution. In some embodiments, the sucralose is present as a powder. In some embodiments, the formulations further comprise an anticoagulant. In some embodiments, the anticoagulant is selected from the group consisting of acid citrate dextrose solution (ACD), sodium heparin, sodium fluoride, lithium heparin, tri-potassium ethylenediaminetetraacetic acid (K3EDTA), di-potassium ethylenediaminetetraacetic acid (K2EDTA), hirudin, and sodium polyanethol sulfonate (SPS). In some embodiments, the anticoagulant is acid citrate dextrose solution (ACD). In some embodiments, the anticoagulant is sodium heparin. In some embodiments, the anticoagulant is sodium fluoride. In some embodiments, the anticoagulant is lithium heparin. In some embodiments, the anticoagulant is tri-potassium ethylenediaminetetraacetic acid (K3EDTA). In some embodiments, the anticoagulant is di-potassium ethylenediaminetetraacetic acid (K2EDTA). In some embodiments, the anticoagulant is hirudin. In some embodiments, the anticoagulant is sodium polyanethol sulfonate (SPS). In some embodiments, the formulation is contained within a blood collection tube.


Methods for Preparing Formulations for Reducing Erythrocyte Sedimentation Rate in a Blood Sample

Methods for preparing the formulations described herein for reduction of erythrocyte sedimentation rate in a blood sample employ techniques that are well-known to those skilled in the art and generally use commercially available reagents. In some embodiments, the formulations are prepared as concentrated stock solutions of the formulation reagents, e.g., 2×, 5×, 10×, 20× or the like, so as to be admixed with the blood sample at the appropriate ratios to produce the desired final concentrations of sucralose in the blood sample.


Compositions of Erythrocytes in a Blood Sample with Reduced Sedimentation Rate

Described herein, in some embodiments, are compositions comprising a blood sample and sucralose, wherein the sucralose is at a concentration of about 5 mM sucralose up to, but not including, about 25 mM sucralose. In some embodiments, the compositions further comprise an anticoagulant. In some embodiments, the anticoagulant is selected from the group consisting of acid citrate dextrose solution (ACD), sodium heparin, sodium fluoride, lithium heparin, tri-potassium ethylenediaminetetraacetic acid (K3EDTA), di-potassium ethylenediaminetetraacetic acid (K2EDTA), hirudin, and sodium polyanethol sulfonate (SPS). In some embodiments, the anticoagulant is acid citrate dextrose solution (ACD). In some embodiments, the anticoagulant is acid citrate dextrose solution A (ACD-A). In some embodiments, the anticoagulant is acid citrate dextrose solution B (ACD-B). In some embodiments, the anticoagulant is sodium heparin. In some embodiments, the anticoagulant is sodium fluoride. In some embodiments, the anticoagulant is lithium heparin. In some embodiments, the anticoagulant is tri-potassium ethylenediaminetetraacetic acid (K3EDTA). In some embodiments, the anticoagulant is di-potassium ethylenediaminetetraacetic acid (K2EDTA). In some embodiments, the anticoagulant is hirudin. In some embodiments, the anticoagulant is sodium polyanethol sulfonate (SPS). In some embodiments, the composition is contained within a blood collection tube. In some embodiments, the blood collection tube is an evacuated blood collection tube. In some embodiments, the blood is collected from a subject. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the compositions of one or more erythrocytes in a blood sample with reduced sedimentation rate are stored in the formulations described herein for extended periods of time before analysis in, for example, a microfluidic device.


Articles of Manufacture

In certain embodiments, articles of manufacture are provided, which comprise a formulation provided herein, contained within a suitable blood collection tube, container or vessel for collection of a biological sample. In some embodiments, these articles of manufacture are used for reducing sedimentation rate of one or more erythrocytes in a blood sample at the time of biological sample collection. In certain embodiments, the blood collection tube is an evacuated blood tube having less than atmospheric pressure to withdraw a predetermined volume of whole blood. In some embodiments, the blood collection tube contains about 28.6 mg of sucralose powder and the blood collection tube is of a size to contain a blood draw volume of 3.0 mL blood to produce a final sucralose concentration of about 24 mM after the addition of 3.0 mL blood. In some embodiments, the blood collection tube contains about 33.4 mg of sucralose powder and the blood collection tube is of a size to contain a blood draw volume of 3.5 mL blood. In some embodiments, the blood collection tube contains about 42.9 mg of sucralose powder and the blood collection tube is of a size to contain a blood draw volume of 4.5 mL blood. In some embodiments, the blood collection tube contains about 52.4 mg of sucralose powder and the blood collection tube is of a size to contain a blood draw volume of 5.5 mL blood. In some embodiments, the blood collection tube contains about 95.4 mg of sucralose powder and the blood collection tube is of a size to contain a blood draw volume of 10 mL blood. In some embodiments, these articles of manufacture are used in the kits and methods described herein.


Kits

In certain embodiments, there are provided kits comprising any one of the articles of manufacture described herein and a package insert. In some embodiments, the components of the kit are supplied in a container. In some embodiments, the container is a compartmentalized plastic enclosure. In some embodiments, the container includes a hermetically sealable cover so that the contents of the kit can be sterilized and sealed for storage.


Methods for Reducing Sedimentation Rate of Erythrocytes in a Blood Sample

Described herein, in some embodiments, are in vitro methods for reducing the erythrocyte sedimentation rate in a blood sample, comprising: combining a sample of blood with an amount of a formulation comprising sucralose, wherein the amount is sufficient to produce a treated blood sample having a sucralose concentration of at least about 5 mM sucralose, thereby reducing the erythrocyte sedimentation rate as compared to erythrocyte sedimentation rate in an untreated blood sample. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 50 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 25 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose up to but not including 25 mM sucralose. In some embodiments, erythrocyte sedimentation rate is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the erythrocyte sedimentation rate of the untreated blood sample. In some embodiments, the formulation is a powder. In some embodiments, the formulation is a solution. In some embodiments, the solution is an aqueous solution. In some embodiments, the formulation consists of sucralose. In some embodiments, the formulation further comprises an anticoagulant. In some embodiments, the anticoagulant is selected from the group consisting of acid citrate dextrose solution (ACD), sodium heparin, sodium fluoride, lithium heparin, tri-potassium ethylenediaminetetraacetic acid (K3EDTA), di-potassium ethylenediaminetetraacetic acid (K2EDTA), hirudin, and sodium polyanethol sulfonate (SPS). In some embodiments, the anticoagulant is acid citrate dextrose solution (ACD). In some embodiments, the anticoagulant is sodium heparin. In some embodiments, the anticoagulant is sodium fluoride. In some embodiments, the anticoagulant is lithium heparin. In some embodiments, the anticoagulant is tri-potassium ethylenediaminetetraacetic acid (K3EDTA). In some embodiments, the anticoagulant is di-potassium ethylenediaminetetraacetic acid (K2EDTA). In some embodiments, the anticoagulant is hirudin. In some embodiments, the anticoagulant is sodium polyanethol sulfonate (SPS). In some embodiments, the formulation is contained within a blood collection tube, and the combining step occurs within the blood collection tube. In some embodiments, the blood collection tube is an evacuated blood collection tube. In some embodiments, the blood is collected from a subject. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.


Described herein, in some embodiments, are methods for maintaining one or more erythrocytes in suspension in a blood sample, comprising: combining a sample of blood with an amount of a formulation comprising sucralose, wherein the amount is sufficient to produce a treated blood sample having a sucralose concentration of at least about 5 mM sucralose, thereby maintaining the one or more erythrocytes in suspension for a period of at least 30 minutes as compared to an untreated blood sample. In some embodiments, the one or more erythrocytes remain in suspension for a period of at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 7 hours, at least 8 hours, at least 10 hours, at least 12 hours, at least 24 hours or at least 48 hours. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose to about 25 mM sucralose. In some embodiments, the treated blood sample has a sucralose concentration of about 5 mM sucralose up to but not including 25 mM sucralose. In some embodiments, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% of the one or more erythrocytes remain in suspension in the treated blood sample as compared to the untreated blood sample. In some embodiments, the formulation is a powder. In some embodiments, the formulation is a solution. In some embodiments, the solution is an aqueous solution. In some embodiments, the formulation consists of sucralose. In some embodiments, the formulation further comprises an anticoagulant. In some embodiments, the anticoagulant is selected from the group consisting of acid citrate dextrose solution (ACD), sodium heparin, sodium fluoride, lithium heparin, tri-potassium ethylenediaminetetraacetic acid (K3EDTA), di-potassium ethylenediaminetetraacetic acid (K2EDTA), hirudin, and sodium polyanethol sulfonate (SPS). In some embodiments, the anticoagulant is acid citrate dextrose solution (ACD). In some embodiments, the anticoagulant is sodium heparin. In some embodiments, the anticoagulant is sodium fluoride. In some embodiments, the anticoagulant is lithium heparin. In some embodiments, the anticoagulant is tri-potassium ethylenediaminetetraacetic acid (K3EDTA). In some embodiments, the anticoagulant is di-potassium ethylenediaminetetraacetic acid (K2EDTA). In some embodiments, the anticoagulant is hirudin. In some embodiments, the anticoagulant is sodium polyanethol sulfonate (SPS). In some embodiments, the formulation is contained within a blood collection tube, and the combining step occurs within the blood collection tube. In some embodiments, the blood collection tube is an evacuated blood collection tube. In some embodiments, the blood sample is collected from a subject. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.


Blood collection tubes, bags, containers and vessels are well-known in the art and have been employed by medical practitioners for decades. Blood collected for reduction of erythrocyte sedimentation rate may be obtained using any method or apparatus commonly employed by those skilled in the art such as venipuncture or finger prick. In some embodiments, when the blood is collected by venipuncture, the formulation is located inside the blood collection tube, e.g., an evacuated tube (VACUTAINER® blood collection tube, Becton Dickinson or VACUETTE® blood collection tube, Greiner Bio-One) at the time that the blood sample is obtained from the subject. In some embodiments, when the blood is collected by venipuncture, the formulations are added to an already obtained whole blood sample, either immediately or shortly after it is withdrawn.


In some embodiments, the methods as described herein use the articles of manufacture and kits disclosed.


The following Examples are presented by way of illustration and not limitation.


Example 1
Reduction of Erythrocyte Sedimentation Rate in Whole Blood by Addition of Sucralose

This Example describes reduction of erythrocyte sedimentation in whole blood by addition of sucralose.


Fresh blood was collected into BD K2EDTA VACUTAINER® tubes and pooled. Blood and a solution of 0.5 M sucralose were mixed at a ratio of 20:1 by aliquotting 952 μL of fresh blood into 2 mL centrifuge tubes containing 48 μL of formulation, resulting in a concentration of about 24 mM sucralose. 48 μL of PBS and 0.9% saline served as controls. Blood with no formulation (NF) added served as an additional control. The filled centrifuge tubes were gently inverted five times to mix and stored upright on the benchtop at approximately 25° C. Tubes were photographed at 0 hours (FIG. 1A), 6 hours (FIG. 1B), and 24 hours (FIG. 1C) against a white background for visual analysis of sedimentation rate.


As shown in FIGS. 1A-C, whole blood collected in K2EDTA tubes containing sucralose had lower sedimentation rate of the erythrocytes after storage of the aliquots at ambient temperature for 6 hours and 24 hours compared to whole blood only (NF) or whole blood following addition of either PBS or saline.


Example 2
Effect of Sucralose Concentration and Other Saccharides on Reduction of Erythrocyte Sedimentation Rate

This Example illustrates the effect on sucralose concentration and other saccharides on reduction of erythrocyte sedimentation rate in whole blood.


Fresh blood was collected into BD K2EDTA VACUTAINER® tubes and pooled. 952 μL of fresh blood was aliquot into 2 mL centrifuge tubes, each containing 48 μL of sucralose at the indicated concentration in FIG. 2, or the indicated saccharide (ML848, a di-chlorinated monosaccharide, or DG783, a mono-fluorinated monosaccharide) at the indicated concentration. Sucralose solutions of different concentrations were prepared by dilution of 0.5 M sucralose to 10 mM in water. Formulations were adjusted to 300 mOsmol with NaCl, with the exception of formulations of the highest concentration that had an osmolarity of 500 mOsmol. 48 μL of PBS and 0.9% saline served as controls. Final concentrations of sucralose or the indicated saccharide shown in FIG. 2 were as follows (from left to right): 24 mM sucralose, 12 mM sucralose, 6.24 mM sucralose, 2.88 mM sucralose, 1.44 mM sucralose, 0.96 mM sucralose, 0.48 mM sucralose, 24 mM sucrose, 2.4 mM sucrose, 24 mM trehalose, 24 mM melezitose, 4.8 mM ML848, and 24 mM DG783.


The filled centrifuge tubes were gently inverted five times to mix and stored upright on the benchtop at approximately 25° C. Tubes were photographed at 1 hour (FIG. 2, upper panel) and 6 hours (FIG. 2, center panel) against a white background for visual analysis of sedimentation rate. After 7 hours of storage, tubes were centrifuged for 20 min at 3000 rpm to determine the effect of hemolysis on sedimentation rate by visual analysis (FIG. 2, lower panel).



FIG. 2 shows that whole blood collected in K2EDTA tubes containing high concentrations of sucralose had lower sedimentation rate of erythrocytes after storage of aliquots at ambient temperature for 1 hour (upper panel) and 6 hours (center panel). Lower sedimentation rate of erythrocytes was not observed in samples that had final sucralose concentrations below 5 mM, or in samples following addition of sucrose, trehalose, melezitose, ML848, DG783, PBS, or saline to whole blood.


Homogeneity of whole blood in the presence of a high concentration of sucralose was not due to excessive hemolysis of erythrocytes, as shown by centrifugation of the sample after 7 hours of storage (FIG. 2, lower panel). Centrifugation resulted in clear separation of plasma without coloration of the plasma layer similar to that seen for the saline and PBS sample controls (FIG. 2, lower panel). Significant hemolysis was not seen at final sucralose concentrations at or below 40 mM.


Example 3
Effect of Sucralose Added as a Powder on Reduction of Erythrocyte Sedimentation Rate

This Example describes the effect of addition of sucralose in powder form on reduction of erythrocyte sedimentation rate in whole blood.


Fresh blood was collected into BD K2EDTA VACUTAINER® tubes and pooled. 1 mL of fresh blood was aliquotted into 2 mL centrifuge tubes containing sucralose powder. Final concentrations of sucralose ranged from 7.5 mM to 100 mM, corresponding to 3.0 mg to 39.8 mg per mL of blood. The no formulation (NF) control sample received no addition of sucralose. Tubes were inverted at least five times until no visible undissolved material remained at the bottom of the tubes. Tubes were stored upright on the benchtop at approximately 25° C. Tubes were photographed at 1 hour (FIG. 3, upper panel) and 6 hours (FIG. 3, lower panel) against a white background for visual analysis of sedimentation rate.


Data in FIG. 3 shows that the rate of erythrocyte sedimentation was inversely proportional to the concentration of sucralose. At a sucralose concentration of 24 mM or greater, homogeneity of whole blood samples stored at ambient temperatures for 6 hours was observed, while lower concentrations of sucralose resulted in separation of the erythrocyte and plasma layers.


Example 4
Effect of Blood Collection Conditions on Reduction of Erythrocyte Sedimentation Rate

This Example describes the effect of different anticoagulants present at the time of blood collection on reduction of erythrocyte sedimentation rate in whole blood.


To screen for collection conditions, fresh blood was collected into a series of BD VACUTAINER® or Greiner Bio-One VACUETTE® low-volume blood collection tubes containing different anticoagulants, including acid citrate dextrose solution B (ACD-B), tri-potassium ethylenediaminetetraacetic acid (K3EDTA), sodium heparin (NaHep), lithium heparin (LiHep), sodium fluoride (NaF), and sodium polyanethol sulfonate (SPS). Collection into tubes containing di-potassium ethylenediaminetetraacetic acid (K2EDTA) served as a control. 9524 of fresh blood was aliquot into 2 mL centrifuge tubes containing 48 μL of 0.5 M sucralose or PBS. No formulation (NF) added served as an additional control. The filled centrifuge tubes were gently inverted five times to mix and stored upright on the benchtop at approximately 25° C. Tubes were photographed at 2 hours (FIG. 4, upper panel) and 8 hours (FIG. 4, lower panel) against a white background for visual analysis of sedimentation rate. As shown in FIG. 4, addition of 0.5 M sucralose, for a final sucralose concentration of 24 mM in the treated sample, resulted in reduction of erythrocyte sedimentation rate for each anticoagulant present in the blood collection tube at the time of blood collection. By contrast, addition of PBS had no effect on erythrocyte sedimentation rate.


Example 5
Effect of Sucralose Compared to Polyols and Halogenated Polyols on Reduction of Erythrocyte Sedimentation Rate

This Example describes the effect of sucralose compared to the effect of polyols and halogenated polyols on reduction of erythrocyte sedimentation rate in whole blood.


Fresh blood was collected into BD K2EDTA VACUTAINER® tubes and pooled. 9524 of fresh blood was aliquot into 2 mL centrifuge tubes containing 484 of a solution of 0.5 M sucralose, the indicated polyol, or the indicated halogenated polyol. Additives at 0.25 M were adjusted to 300 mOsmol with NaCl. PBS and no formulation (NF) added served as controls. The filled centrifuge tubes were gently inverted five times to mix and stored upright on the benchtop at approximately 25° C. Tubes were photographed at 2 hours against a white background for visual analysis of sedimentation rate.


Data in FIG. 5 shows that addition of a solution of 0.5 M sucralose, for a final sucralose concentration of 24 mM in the treated sample, resulted in reduced erythrocyte sedimentation rate. By contrast, addition of indicated polyols or halogenated polyols had no apparent effect on erythrocyte sedimentation.


Unless the context requires otherwise, throughout the present specification and claims, the word “comprise” and variations thereof, such as, “comprises” and “comprising,” which is used interchangeably with “including,” “containing,” or “characterized by,” is inclusive or open-ended language and does not exclude additional, unrecited elements or method steps. The phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. The phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. The present disclosure contemplates embodiments of the invention compositions and methods corresponding to the scope of each of these phrases. Thus, a composition or method comprising recited elements or steps contemplates particular embodiments in which the composition or method consists essentially of or consists of those elements or steps.


Reference throughout this specification to “one embodiment” or “an embodiment” or “an aspect” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.


The various embodiments described above can be combined to provide further embodiments. These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.


While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims
  • 1. A method for analyzing a blood sample, the method comprising: injecting a treated blood sample into a microfluidics device; andanalyzing the treated blood sample;wherein the treated blood sample comprises a blood sample from a subject and a formulation comprising from about 5 mM to about 100 mM sucralose.
  • 2. The method of claim 1, wherein the treated blood sample is stored before injection into the microfluidics device.
  • 3. The method of claim 2, wherein the treated blood sample is stored for about 10 minutes to about 48 hours.
  • 4. The method of claim 2, wherein the treated blood sample is stored for about 30 minutes to about 24 hours.
  • 5. The method of claim 2, wherein the treated blood sample is stored for about 1 hour to about 12 hours.
  • 6. The method of claim 2, wherein the treated blood sample is stored at ambient temperature.
  • 7. The method of claim 1, wherein the treated sample is not mixed before injection into the microfluidics device.
  • 8. The method of claim 1, wherein the treated blood sample comprises a reduced erythrocyte sedimentation rate as compared to an untreated sample, thereby reducing clogging in the microfluidics device.
  • 9. The method of claim 8, wherein the erythrocyte sedimentation rate is reduced by at least 10% compared to the erythrocyte sedimentation rate of an untreated blood sample.
  • 10. The method of claim 8, wherein the erythrocyte sedimentation rate is reduced by at least 25% compared to the erythrocyte sedimentation rate of an untreated blood sample.
  • 11. The method of claim 8, wherein the erythrocyte sedimentation rate is reduced by at least 50% compared to the erythrocyte sedimentation rate of an untreated blood sample.
  • 12. The method of claim 1, wherein the subject is a human subject.
  • 13. The method of claim 12, wherein the human subject has been diagnosed with a disease that correlates with an increased rate of erythrocyte sedimentation.
  • 14. The method of claim 13, wherein the disease is selected from the group consisting of multiple myeloma, temporal arteritis, polymyalgia rheumatica, systemic lupus erythematosus, and rheumatoid arthritis.
  • 15. The method of claim 1, wherein the formulation comprises from about 5 mM to about 50 mM sucralose.
  • 16. The method of claim 1, wherein the formulation comprises from about 5 mM to about 25 mM sucralose.
  • 17. The method of claim 1, wherein the formulation further comprises an anticoagulant.
  • 18. The method of claim 17, wherein the anticoagulant is selected from the group consisting of acid citrate dextrose solution (ACD), sodium heparin, sodium fluoride, lithium heparin, tri-potassium ethylenediaminetetraacetic acid (K3EDTA), di-potassium ethylenediaminetetraacetic acid (K2EDTA), hirudin, and sodium polyanethol sulfonate (SPS).
  • 19. The method of claim 1, wherein the treated blood sample comprises at least about 2.0 mg of the sucralose per ml of the subject's blood sample.
  • 20. The method of claim 1, wherein, when combined with the blood sample to form the treated blood sample, the formulation is in the form of a powder, a solid, a lyophilized form, or a solution and contained in a blood collection tube.
CROSS-REFERENCE

This application is a continuation of U.S. patent application Ser. No. 15/750,590, filed May 31, 2018, now allowed, which is a § 371 U.S. National Entry of PCT/US2016/065198, filed Dec. 6, 2016, which claims the benefit of U.S. Provisional Application No. 62/264,786, filed Dec. 8, 2015, each of which is incorporated by reference herein in its entirety.

US Referenced Citations (356)
Number Name Date Kind
3673158 Arthur et al. Jun 1972 A
3700555 Rudolph et al. Oct 1972 A
4024548 Alonso et al. May 1977 A
4040785 Kim et al. Aug 1977 A
4127502 Li et al. Nov 1978 A
4185964 Lancaster Jan 1980 A
4257958 Powell Mar 1981 A
4264560 Natelson Apr 1981 A
4342740 Narra et al. Aug 1982 A
4451569 Kobayashi et al. May 1984 A
4473552 Jost Sep 1984 A
4683195 Mullis et al. Jul 1987 A
4683202 Mullis Jul 1987 A
4800159 Mullis et al. Jan 1989 A
4801428 Homolko et al. Jan 1989 A
4806343 Carpenter et al. Feb 1989 A
4842758 Crutzen Jun 1989 A
4889818 Gelfand et al. Dec 1989 A
4891319 Roser Jan 1990 A
4898813 Albarella et al. Feb 1990 A
4933145 Uchida et al. Jun 1990 A
4962020 Tabor et al. Oct 1990 A
4962022 Fleming et al. Oct 1990 A
4965188 Mullis et al. Oct 1990 A
4978688 Louderback Dec 1990 A
5039704 Smith et al. Aug 1991 A
5047342 Chatterjee Sep 1991 A
5071648 Rosenblatt Dec 1991 A
5078997 Hora et al. Jan 1992 A
5079352 Gelfand et al. Jan 1992 A
5089407 Baker et al. Feb 1992 A
5096670 Harris et al. Mar 1992 A
5096744 Takei et al. Mar 1992 A
5098893 Franks et al. Mar 1992 A
5147803 Enomoto Sep 1992 A
5198353 Hawkins et al. Mar 1993 A
5200399 Wettlaufer et al. Apr 1993 A
5240843 Gibson et al. Aug 1993 A
5242792 Rudolph et al. Sep 1993 A
5270179 Chatterjee Dec 1993 A
5290765 Wettlaufer et al. Mar 1994 A
5315505 Pratt et al. May 1994 A
5351801 Markin et al. Oct 1994 A
5374553 Gelfand et al. Dec 1994 A
5397711 Finckh Mar 1995 A
5403706 Wilk et al. Apr 1995 A
5409818 Davey et al. Apr 1995 A
5418141 Zweig et al. May 1995 A
5428063 Barak et al. Jun 1995 A
5436149 Barnes Jul 1995 A
5455166 Walker Oct 1995 A
5496562 Burgoyne Mar 1996 A
5498523 Tabor et al. Mar 1996 A
5512462 Cheng Apr 1996 A
5516644 Yamauchi et al. May 1996 A
5529166 Markin et al. Jun 1996 A
5541290 Harbeson et al. Jul 1996 A
5556771 Shen et al. Sep 1996 A
5593824 Treml et al. Jan 1997 A
5614365 Tabor et al. Mar 1997 A
5614387 Shen et al. Mar 1997 A
5677124 Dubois et al. Oct 1997 A
5684045 Smith et al. Nov 1997 A
5688516 Raad et al. Nov 1997 A
5705366 Backus Jan 1998 A
5728822 Macfarlane Mar 1998 A
5741462 Nova et al. Apr 1998 A
5751629 Nova et al. May 1998 A
5763157 Treml et al. Jun 1998 A
5777099 Mehra Jul 1998 A
5777303 Berney Jul 1998 A
5779983 Dufresne et al. Jul 1998 A
5789172 Still et al. Aug 1998 A
5789414 Lapidot et al. Aug 1998 A
5798035 Kirk et al. Aug 1998 A
5814502 Hoeltke et al. Sep 1998 A
5827874 Meyer et al. Oct 1998 A
5834254 Shen et al. Nov 1998 A
5837546 Allen et al. Nov 1998 A
5849517 Ryan Dec 1998 A
5856102 Bierke-Nelson et al. Jan 1999 A
5861251 Park et al. Jan 1999 A
5863799 Hengstenberg Jan 1999 A
5874214 Nova et al. Feb 1999 A
5876992 De et al. Mar 1999 A
5914272 Dufresne et al. Jun 1999 A
5918273 Horn Jun 1999 A
5939259 Harvey et al. Aug 1999 A
5945515 Chomczynski Aug 1999 A
5948614 Chatterjee Sep 1999 A
5955448 Colaco et al. Sep 1999 A
5985214 Stylli et al. Nov 1999 A
5991729 Barry et al. Nov 1999 A
6013488 Hayashizaki Jan 2000 A
6015668 Hughes et al. Jan 2000 A
6017496 Nova et al. Jan 2000 A
6025129 Nova et al. Feb 2000 A
6037168 Brown Mar 2000 A
6050956 Ikegami et al. Apr 2000 A
6057117 Harrison et al. May 2000 A
6057159 Lepre May 2000 A
6071428 Franks et al. Jun 2000 A
6077235 Serpentino et al. Jun 2000 A
6090925 Woiszwillo et al. Jul 2000 A
6124089 Ryan Sep 2000 A
6127155 Gelfand et al. Oct 2000 A
6143817 Hallam et al. Nov 2000 A
6153412 Park et al. Nov 2000 A
6153618 Schultz et al. Nov 2000 A
6156345 Chudzik et al. Dec 2000 A
6166117 Miyazaki Dec 2000 A
6168922 Harvey et al. Jan 2001 B1
6197229 Ando et al. Mar 2001 B1
6204375 Lader Mar 2001 B1
6221599 Hayashizaki Apr 2001 B1
6242235 Shultz et al. Jun 2001 B1
6251599 Chen et al. Jun 2001 B1
6258930 Gauch et al. Jul 2001 B1
6284459 Nova et al. Sep 2001 B1
6294203 Burgoyne Sep 2001 B1
6294338 Nunomura Sep 2001 B1
6310060 Barrett et al. Oct 2001 B1
6313102 Colaco et al. Nov 2001 B1
6322983 Burgoyne Nov 2001 B1
6323039 Dykens et al. Nov 2001 B1
6329139 Nova et al. Dec 2001 B1
6331273 Nova et al. Dec 2001 B1
6352854 Nova et al. Mar 2002 B1
6366440 Kung Apr 2002 B1
6372428 Nova et al. Apr 2002 B1
6372437 Hayashizaki Apr 2002 B2
6380858 Yarin et al. Apr 2002 B1
6416714 Nova et al. Jul 2002 B1
6417185 Goff et al. Jul 2002 B1
6426210 Franks et al. Jul 2002 B1
6440966 Barrett et al. Aug 2002 B1
6447726 Delucas et al. Sep 2002 B1
6447804 Burgoyne Sep 2002 B1
6448245 Depetrillo et al. Sep 2002 B1
RE37872 Franks et al. Oct 2002 E
6458556 Hayashizaki Oct 2002 B1
6465231 Harrison et al. Oct 2002 B2
6475716 Seki Nov 2002 B1
6489344 Nuss et al. Dec 2002 B1
6503411 Franks et al. Jan 2003 B1
6503702 Stewart Jan 2003 B1
6528309 Levine Mar 2003 B2
6534483 Bruno et al. Mar 2003 B1
6535129 Petrick Mar 2003 B1
6602718 Augello et al. Aug 2003 B1
6608632 Daly et al. Aug 2003 B2
6610531 Mateczun et al. Aug 2003 B1
6617170 Augello et al. Sep 2003 B2
6627226 Burgoyne et al. Sep 2003 B2
6627398 Wilusz et al. Sep 2003 B1
6638945 Gibson Oct 2003 B1
6645717 Smith et al. Nov 2003 B1
6649406 Williams et al. Nov 2003 B1
6653062 Depablo et al. Nov 2003 B1
6664099 Worrall Dec 2003 B1
6667167 Sorensen et al. Dec 2003 B1
6682730 Mickle et al. Jan 2004 B2
6689343 Allred et al. Feb 2004 B1
6689353 Wang et al. Feb 2004 B1
6696028 Bara Feb 2004 B2
6746841 Fomovskaia et al. Jun 2004 B1
6746851 Tseung et al. Jun 2004 B1
6750059 Blakesley et al. Jun 2004 B1
6776959 Helftenbein Aug 2004 B1
6787305 Li et al. Sep 2004 B1
6800632 Nuss et al. Oct 2004 B2
6803200 Xia et al. Oct 2004 B2
6821479 Smith et al. Nov 2004 B1
6821789 Augello et al. Nov 2004 B2
6852833 Machida et al. Feb 2005 B1
6858634 Asrar et al. Feb 2005 B2
6861213 Oelmuller et al. Mar 2005 B2
6862789 Hering et al. Mar 2005 B1
6872357 Bronshtein et al. Mar 2005 B1
6896894 Brody et al. May 2005 B2
6919172 Depablo et al. Jul 2005 B2
6942964 Ward et al. Sep 2005 B1
6949544 Bethiel et al. Sep 2005 B2
6949547 Nuss et al. Sep 2005 B2
7001770 Atencio et al. Feb 2006 B1
7001905 Biwersi et al. Feb 2006 B2
7011825 Yamazaki et al. Mar 2006 B2
7037918 Nuss et al. May 2006 B2
7045519 Nuss et al. May 2006 B2
7049065 Hayashizaki May 2006 B2
7083106 Albany Aug 2006 B2
7098033 Chen et al. Aug 2006 B2
7101693 Cicerone et al. Sep 2006 B2
7129242 Yoshitaka et al. Oct 2006 B2
7142987 Eggers Nov 2006 B2
7150980 Lapidot et al. Dec 2006 B1
7169584 Ward et al. Jan 2007 B2
7169816 Barrett et al. Jan 2007 B2
RE39497 Franks et al. Feb 2007 E
7172999 Mattern et al. Feb 2007 B2
7258873 Truong-Le Vu et al. Aug 2007 B2
7270953 Hollaender et al. Sep 2007 B2
7282371 Helftenbein Oct 2007 B2
7326418 Franzoso et al. Feb 2008 B2
7384603 Klein et al. Jun 2008 B2
7425557 Nuss et al. Sep 2008 B2
7476754 Herradon et al. Jan 2009 B2
7521460 Langham et al. Apr 2009 B2
7592455 Brookings et al. Sep 2009 B2
7728013 Blatt et al. Jun 2010 B2
7745663 Isshiki et al. Jun 2010 B2
7795256 Alexander et al. Sep 2010 B2
7803839 Aay et al. Sep 2010 B2
7846703 Kobayashi et al. Dec 2010 B2
7897624 Yan et al. Mar 2011 B2
7919294 Franco et al. Apr 2011 B2
7932266 Garcia et al. Apr 2011 B2
7972828 Ward et al. Jul 2011 B2
8143271 Ibrahim et al. Mar 2012 B2
RE43389 Helftenbein May 2012 E
8178555 Chang et al. May 2012 B2
8378108 Corkey et al. Feb 2013 B2
8394822 Hutchings et al. Mar 2013 B2
8440665 Corkey et al. May 2013 B2
8492427 Gancia et al. Jul 2013 B2
8519125 Whitney et al. Aug 2013 B2
8530480 Kamenecka et al. Sep 2013 B2
8598360 Corkey et al. Dec 2013 B2
8642584 Aftab et al. Feb 2014 B2
8664244 Chen Mar 2014 B2
8827874 Nishimura Sep 2014 B2
8900856 Muller-Cohn et al. Dec 2014 B2
9078426 Muller-Cohn et al. Jul 2015 B2
9376709 Whitney et al. Jun 2016 B2
9725703 Whitney et al. Aug 2017 B2
9845489 Whitney et al. Dec 2017 B2
20010038858 Roser et al. Nov 2001 A1
20020039771 Peters et al. Apr 2002 A1
20020055118 Eym May 2002 A1
20020076819 Bowman et al. Jun 2002 A1
20020081565 Barnea et al. Jun 2002 A1
20020094533 Hess et al. Jul 2002 A1
20020103086 Asrar et al. Aug 2002 A1
20020182258 Lunsford et al. Dec 2002 A1
20020197628 Stewart Dec 2002 A1
20030022148 Seki Jan 2003 A1
20030031697 Chudzik et al. Feb 2003 A1
20030032147 Sauer et al. Feb 2003 A1
20030059468 Mattern et al. Mar 2003 A1
20030091971 Xia et al. May 2003 A1
20030119042 Franco et al. Jun 2003 A1
20030129755 Sadler et al. Jul 2003 A1
20030138805 Loffert et al. Jul 2003 A1
20030157088 Elliott et al. Aug 2003 A1
20030162284 Dordick et al. Aug 2003 A1
20030163608 Tiwary et al. Aug 2003 A1
20030165482 Rolland et al. Sep 2003 A1
20030175232 Elliott et al. Sep 2003 A1
20030199446 Bunger et al. Oct 2003 A1
20030215369 Eggers et al. Nov 2003 A1
20040014068 Burgoyne Jan 2004 A1
20040058349 Van et al. Mar 2004 A1
20040101966 Davis et al. May 2004 A1
20040110267 Sundar Jun 2004 A1
20040121420 Smith Jun 2004 A1
20040121432 Klein et al. Jun 2004 A1
20040137417 Ryan Jul 2004 A1
20040142475 Barman et al. Jul 2004 A1
20040208792 Linton et al. Oct 2004 A1
20040228794 Weller et al. Nov 2004 A1
20040241713 Mirzabekov et al. Dec 2004 A1
20050026181 Davis et al. Feb 2005 A1
20050053911 Greener et al. Mar 2005 A1
20050084481 Hand et al. Apr 2005 A1
20050086822 Frisner et al. Apr 2005 A1
20050090009 Cormier et al. Apr 2005 A1
20050112610 Lee et al. May 2005 A1
20050124965 Haywood Jun 2005 A1
20050186254 Roser et al. Aug 2005 A1
20050196824 Fisher et al. Sep 2005 A1
20050227269 Lloyd et al. Oct 2005 A1
20050251501 Phillips et al. Nov 2005 A1
20050266031 Dickerson et al. Dec 2005 A1
20050276728 Muller-Cohn et al. Dec 2005 A1
20060014177 Hogan et al. Jan 2006 A1
20060099567 Muller-Cohn et al. May 2006 A1
20060127415 Mayeresse Jun 2006 A1
20060147944 Chomczynski Jul 2006 A1
20060177855 Utermohlen et al. Aug 2006 A1
20060183687 Cory et al. Aug 2006 A1
20060193968 Keogh et al. Aug 2006 A1
20060198891 Ravenelle et al. Sep 2006 A1
20060210429 Hunsley et al. Sep 2006 A1
20060293212 Griese et al. Dec 2006 A1
20070020289 Mattern et al. Jan 2007 A1
20070043216 Bair, Jr. et al. Feb 2007 A1
20070048726 Baust et al. Mar 2007 A1
20070073039 Chisari Mar 2007 A1
20070117173 Levison et al. May 2007 A1
20070135528 Butler et al. Jun 2007 A1
20070212760 Lapidot et al. Sep 2007 A1
20070243178 Ho et al. Oct 2007 A1
20080050737 Arieli et al. Feb 2008 A1
20080064071 Hogrefe et al. Mar 2008 A1
20080146790 Grolz et al. Jun 2008 A1
20080176209 Muller et al. Jul 2008 A1
20080187924 Korfhage et al. Aug 2008 A1
20080227118 Kohno et al. Sep 2008 A1
20080268514 Muller et al. Oct 2008 A1
20080307117 Muller-Cohn et al. Dec 2008 A1
20090010858 Asano Jan 2009 A1
20090226545 Blotsky Sep 2009 A1
20090233283 Rashtchian et al. Sep 2009 A1
20090239208 Mayaudon et al. Sep 2009 A1
20090259023 Su et al. Oct 2009 A1
20090291427 Muller-Cohn et al. Nov 2009 A1
20090298132 Muller-Cohn et al. Dec 2009 A1
20090312285 Fischer et al. Dec 2009 A1
20100099150 Fang et al. Apr 2010 A1
20100159528 Liu et al. Jun 2010 A1
20100159529 Metzler et al. Jun 2010 A1
20100178210 Hogan et al. Jul 2010 A1
20100184069 Fernando et al. Jul 2010 A1
20100196904 Arieli et al. Aug 2010 A1
20100209930 Fernando Aug 2010 A1
20100261252 Long et al. Oct 2010 A1
20100292447 Pitner et al. Nov 2010 A1
20110014676 Cowan et al. Jan 2011 A1
20110027862 Bates et al. Feb 2011 A1
20110059490 Lagunavicius et al. Mar 2011 A1
20110081363 Whitney et al. Apr 2011 A1
20110091356 Kim Apr 2011 A1
20110111410 Ryan May 2011 A1
20110313383 Hofstetter et al. Dec 2011 A1
20120028933 Baust et al. Feb 2012 A1
20120052572 Whitney et al. Mar 2012 A1
20120100522 Saghbini et al. Apr 2012 A1
20120142070 Battrell et al. Jun 2012 A1
20120149004 Gelfand et al. Jun 2012 A1
20120282634 Hughes et al. Nov 2012 A1
20120295328 Wyrich et al. Nov 2012 A1
20130066234 Helftenbein Mar 2013 A1
20130183237 Kazimirova et al. Jul 2013 A1
20130209997 Whitney et al. Aug 2013 A1
20130289265 Li et al. Oct 2013 A1
20140017712 Shoji et al. Jan 2014 A1
20140065627 Whitney et al. Mar 2014 A1
20140141411 Lloyd, Jr. et al. May 2014 A1
20140147856 Forsyth May 2014 A1
20140261474 Gonda Sep 2014 A1
20150329849 Whitney et al. Nov 2015 A1
20160135446 Judy et al. May 2016 A1
20160338342 Whitney et al. Nov 2016 A1
20170196220 Muller et al. Jul 2017 A1
20170198335 Muller Jul 2017 A1
20170202211 Muller Jul 2017 A1
Foreign Referenced Citations (126)
Number Date Country
1022441 Dec 1977 CA
2467563 May 2003 CA
102026619 Apr 2011 CN
102947082 Feb 2013 CN
105491883 Apr 2016 CN
106572650 Apr 2017 CN
2424426 Mar 1975 DE
19834816 Feb 2000 DE
102008029734 Dec 2009 DE
0448146 Sep 1991 EP
0451924 Oct 1991 EP
0329822 Jun 1994 EP
0637750 Feb 1995 EP
0706825 Apr 1996 EP
0236069 May 1997 EP
0774464 May 1997 EP
0875292 Nov 1998 EP
0915167 May 1999 EP
1088060 Apr 2001 EP
0833611 Aug 2001 EP
0684315 Jun 2002 EP
0822861 Nov 2003 EP
1555033 Jul 2005 EP
1082006 Feb 2006 EP
0395736 Aug 2006 EP
1736542 Dec 2006 EP
1758932 Mar 2007 EP
1651712 Oct 2007 EP
2934572 Oct 2015 EP
3007556 Apr 2016 EP
3154338 Apr 2017 EP
3155091 Apr 2017 EP
3155395 Apr 2017 EP
3249054 Nov 2017 EP
2129551 May 1984 GB
S5847492 Mar 1983 JP
S62502633 Oct 1987 JP
H08211065 Aug 1996 JP
H09127106 May 1997 JP
2000500327 Jan 2000 JP
2001050872 Feb 2001 JP
2001247401 Sep 2001 JP
2005-156332 Jun 2005 JP
2009517086 Apr 2009 JP
2009096766 May 2009 JP
2014-519314 Aug 2014 JP
WO-8607462 Dec 1986 WO
WO-8700196 Jan 1987 WO
WO-8701206 Feb 1987 WO
WO-8900012 Jan 1989 WO
WO-8906542 Jul 1989 WO
WO-9005182 May 1990 WO
WO-9114773 Oct 1991 WO
WO-9200091 Jan 1992 WO
WO-9206188 Apr 1992 WO
WO-9206200 Apr 1992 WO
WO 908349 May 1992 WO
WO-9209300 Jun 1992 WO
WO-9211864 Jul 1992 WO
WO-9206188 Oct 1992 WO
WO-9422885 Oct 1994 WO
WO-9501559 Jan 1995 WO
WO-9502046 Jan 1995 WO
WO-9510605 Apr 1995 WO
WO-9516198 Jun 1995 WO
WO-9610640 Apr 1996 WO
WO-9636436 Nov 1996 WO
WO-9700670 Jan 1997 WO
WO-9705248 Feb 1997 WO
WO-9715394 May 1997 WO
WO-9815355 Apr 1998 WO
WO-9824543 Jun 1998 WO
WO-9955346 Nov 1999 WO
WO-9960849 Dec 1999 WO
WO-9967371 Dec 1999 WO
WO-0009746 Feb 2000 WO
WO-0014505 Mar 2000 WO
WO-0020117 Apr 2000 WO
WO-0062023 Oct 2000 WO
WO-0076664 Dec 2000 WO
WO-0137656 May 2001 WO
WO-0194016 Dec 2001 WO
WO-03020874 Mar 2003 WO
WO-03020924 Mar 2003 WO
WO-03056293 Jul 2003 WO
WO-03069344 Aug 2003 WO
WO-03087335 Oct 2003 WO
WO-2004031363 Apr 2004 WO
WO-2004112476 Dec 2004 WO
WO-2005014704 Feb 2005 WO
WO-2005059178 Jun 2005 WO
WO-2005113147 Dec 2005 WO
WO-2005116081 Dec 2005 WO
WO-2006001499 Jan 2006 WO
WO-2007075253 Jul 2007 WO
WO-2007094581 Aug 2007 WO
WO-2008007463 Jan 2008 WO
WO-2008040126 Apr 2008 WO
WO-2008048228 Apr 2008 WO
WO-2008108549 Sep 2008 WO
WO-2009002568 Dec 2008 WO
WO-2009009210 Jan 2009 WO
WO-2009038853 Mar 2009 WO
WO-2010046949 Apr 2010 WO
WO-2010047592 Apr 2010 WO
WO-2010065924 Jun 2010 WO
WO-2010132508 Nov 2010 WO
WO-2010138522 Dec 2010 WO
WO-2012018638 Feb 2012 WO
WO-2012018639 Feb 2012 WO
WO-2012067240 May 2012 WO
WO-2012075407 Jun 2012 WO
WO-2012170907 Dec 2012 WO
WO-2013077290 May 2013 WO
WO 2014049022 Apr 2014 WO
WO 2014083300 Jun 2014 WO
WO-2014100755 Jun 2014 WO
WO-2015002729 Jan 2015 WO
WO 2015119115 Aug 2015 WO
WO-2015175672 Nov 2015 WO
WO-2015191632 Dec 2015 WO
WO-2015191633 Dec 2015 WO
WO-2015191634 Dec 2015 WO
WO-2017100212 Jun 2017 WO
WO-2017100213 Jun 2017 WO
WO-2018081161 May 2018 WO
Non-Patent Literature Citations (228)
Entry
ALA-GLN(Alanyl-Glutamine) Product Catalog. Retrieved from the internet on Feb. 16, 2018, 3 pages.
Allison et al., “Effects of Drying Methods and Additives on Structure and Function of Actin: Mechanisms of Dehydration-Induced Damage and Its Inhibition,” Archives of Biochemistry and Biophysics 358(1):171-181, 1998.
Alvarez-Guerra et al., Design of ionic liquids: an ecotoxicity (Vibrio fischeri) discrimination approach. Green Chem., 13:1507-1516, 2011.
Anchordoquy et al., “Frontiers in Clinical Research—Preservation of DNA,” Cell Preservation Technology 5(4):180-188, 2007.
Ando et al., “PLGA Microspheres Containing Plasmid DNA: Preservation of Supercoiled DNA via Cryopreparatin and Carbohydrate Stabilization,” Journ. Pharm. Sci., 88(1):126-130, 1999.
Anonymous, “Transmucosal polymeric molecular delivery systems,” retrieved from http://www.antiagingresearch.com/hgh/transmucosal.php on Apr. 7, 2005, 2 pages.
“Antibiotics from Prokaryotes.” https://www.boundless.com/microbiology/antimicrobial-drugs/commonly-used-antimicrobial-drugs/antibiotics-from-prokaryotes/, downloaded Aug. 1, 2014, 1 page.
Arakawa et al., “Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs,” Biochimica et Biophysica Acta 1764:1677-1687, 2006.
“Are supplements with amino acid chelated minerals better than those with other forms of minerals?” https://www.consumerlab.com/answers/Are+supplements+with+amino+acid+chelated+minerals+better+than+those+with+other+forms+of+minerals%3F/amino_acid_mineral_chelates/, downloaded Jul. 31, 2014, 1 page.
Asano, “Glycosidase inhibitors: update and perspectives on practical use,” Glycobiology 13(10):93R-104R, 2003.
Balevicius et al., NMR and quantum chemistry study of mesoscopic effects in ionic liquids. J.Phys.Chem., 114:5365-5371, 2010.
Barnes, The fidelity of Taq polymerase catalyzing PCR is improved by an N-terminal deletion. Gene, 112:29-35 (1992).
Baskakov et al., “Forcing Thermodynamically Unfolded Proteins to Fold,” The Journal of Biological Chemistry, 273(9):4831-4834, 1998.
“Borax: Friend or foe?” Momsaware.org webpage, http://www.momsaware.org/household-genera1/139-borax-friend-or-foe.html, downloaded Jul. 31, 2014, 1 page.
Boyd et al., “Stabilization Effect of Polyvinyl Alcohol on Horseradish Peroxidase, Glucose Oxidase, 13-Galactosidase and Alkaline Phosphatase,” Biotechnology Techniques 10(9):693-698, 1996.
Braasch et al. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Bio 8:1-7 (2001).
Branco et al., Preparation and characterization of new room temperature ionic liquids. Chem.Eur.J. 8(16):3671-3677, 2002.
Buhler et al., “Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3,” Journal of Virology 75(19):9502-9508, 2001.
Calfon et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 415:92-96 (2002) (Abstract only).
Carninci et al., “Thermostabilization and thermoactivation of thermolabile enzymes by trehalose and its application for the synthesis of full length cDNA,” Proc. Natl. Acad. Sci. USA 95:520-524, 1998.
Carpenter et al., “Stabilization of phosphofructokinase during air-drying with sugars and sugar/transition metal mixtures,” Cryobiology 24(5):455-464, 1987. (Abstract).
Catalan et al., “Progress towards a generalized solvent polarity scale: The solvatochromism of 2-(dimethylamino)-7-nitrofluorene and its homomorph 2-fluoro-7-nitrofluorene”, Liebigs Ann. 1995(2):241-252, 1995.
Catalan, Solvent effects based on pure solvent scales. In: Handbook of Solvents. Wypych G., ed. Toronto: ChemTec Publishing and New York: William Andrew Publishing. 2001: 583-616.
Cavalieri et al., “Chaperone-like activity of nanoparticles of hydrophobized poly(vinyl alcohol),” Soft Matter 3:718-724, 2007.
Chen et al., “Stabilization of Recombinant Human Keratinocyte Growth Factor by Osmolytes andSalts,” Journal of Pharmaceutical Sciences, 85(4):419-426, 1996.
Cheng et al., “Chip PCR. II. Investigation of different PCR amplification systems in microfabricated silicon-glass chips,” Nucleic Acids Res. 24:380-385, 1996.
Chung et al., Lack of Dramatic Enrichment of Fetal DNA in Maternal Plasma by Formaldehyde Treatment, Clinical Chemistry 51(3):655-658 (2005).
Clement et al. Bioactive isomalabaricane triterpenoids from Rhabdastrella globostellata that stabile the binding of DNA polymerase beta to DNA. J. Nat. Prod., 2006, 69(3):373-6.
Clement et al., Following nature's lead: Generating compounds for stabilizing biomolecules. Biopreservation and Biobanking, 2012, 10(4):395-402.
Cohen et al., “Diffusion NMR Spectroscopy in Supramolecular and Combinatorial Chemistry: An Old Parameter—New Insights,” Angew. Chem. Int. Ed., 44:520-554, 2005.
Dagani, “Stir, Heat—But No Need to Dissolve,” Chemical & Engineering News 81(5): 3 pages, 2003.
Dankwardt et al., “Stabilization of enzyme immunoassays for atrazine,” Analytica Chimica Acta 362:35-45, 1998.
Daugherty et al., “Formulation and delivery issues for monoclonal antibody therapeutics,” Advanced Drug Delivery Reviews 58:686-706, 2006.
De Sanctis et al., “Influence of Glycerol on the Structure and Redox Properties of Horse Heart Cytochrome c. A Circular Dichroism and Electrochemical Study,” Journal of Protein Chemistry, 15(7):599-606, 1996.
Degim et al., “Controlled Delivery of Peptides and Proteins,” Current Pharmaceutical Design 13:99-117, 2007.
Del Vigna de Almeida et al., Saliva composition and functions: A comprehensive review. The Journal of Contemporary Dental Practice, 9(3):72-80, 2008.
DePaz et al., “Effects of drying methods and additives on the structure, function, and storage stability of subtilisin: role of protein conformation and molecular mobility,” Enzyme and Microbial Technology 31:765-774, 2002.
Di Tullio et al., “Molecular recognition by mass spectrometry,” J. Mass Spectrom, 40(7):845-865, 2005.
DNA learning center, “Radiation can cause DNA mutations, 3D animation with narration.” http://www.dnalc.org/view/15529-Radiation-can-cause-DNA-mutations-3D-animation-with-narration.html, downloaded Aug. 1, 2014, 1 page.
Dong et al., “Biosynthesis of the Validamycins: Identification of Intermediates in the Biosynthesis of Validamycin A by Streptomyces hygroscopicus var. limoneus,” J. Am. Chem. Soc. 123:2733-2742, 2001.
Dowell et al. Otitis media—principles of judicious use of antimicrobial agents. Pedatrics. 101 Suppl. 1: 165-171, 1998.
Dowell et al. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pedatrics. 101 Suppl. 1: 163-165, 1998.
Dyke et al., “Solvent-Free Functionalization of Carbon Nanotubes,” J. Am. Chem. Soc. 125:1156-1157, 2003.
El-Bashiti, “Trehalose Metabolism In Wheat and Identification Of Trehalose Metabolizing Enzymes Under Abiotic Stress Conditions,” Thesis, The Graduate School of Natural and Applied Sciences of the Middle East Technical University, Jul. 2003, 140 pages.
Ellison et al., Buffer capacities of human blood and plasma. Clinical Chemistry, 4(6):452-461, 1958.
Elzie et al., “The N-terminus of thrombospondin: the domain stands apart,” The International Journal of Biochemistry & Cell Biology 36:1090-1101, 2004.
EP11815081.2 Extended European Search Report dated Nov. 5, 2013.
European Patent Application No. 08826300.9 Supplementary Search Report dated Oct. 26, 2010.
European Patent Application No. 10775442.6 Extended European Search Report dated Jan. 21, 2014.
European Patent Application No. 11815082.0 Extended European Search Report dated Nov. 5, 2013.
European Patent Application No. 13865767.1 extended European Search Report dated Oct. 24, 2016.
European Patent Application No. 14819510.0 extended European Search Report dated Feb. 7, 2017.
European Patent Application No. 14819510.0 partial supplementary European Search Report dated Nov. 4, 2016.
European Patent Application No. 15805897.4 extended European Search Report dated Oct. 17, 2017.
European Patent Application No. 17172030.3 extended European Search Report dated Oct. 13, 2017.
Flaman et al., A rapid PCR fidelity assay. Nucleic Acids Research, 22(15): 3259-3260 (1994).
“Foods high in glycolic acid.” http://www.ehow.com/list_5815634_foods-high-glycolic-acid.html , downloaded Jul. 31, 2014, 1 page.
Frye et al., “The kinetic basis for the stabilization of staphylococcal nuclease by xylose,” Protein Science, 6:789-793, 1997.
Galinski et al., “1,4,5,6-Tetrahydro-2-methyl-4-pyrimidinecarboxylic acid. A novel cyclic amino acid from halophilic phototrophic bacteria of the genus Ectothiorhodospira,” Eur. J. Biochem., 149:135-139, 1985.
Garcia de Castro et al., “Anhydrobiotic Engineering of Gram-Negative Bacteria,” Applied and Environmental Microbiology 66(9):4142-4144, 2000.
Gerard et al., cDNA synthesis by moloney murine leukemia virus RNase H-minus reverse transcriptase possessing full DNA polymerase activity. Focus, 14(1): 91-93 (1992).
Godfrey, “Solvent selection via miscibility number,” Chem. Technol. 2(6):359-363, 1972.
Goller et al, Protection of a model enzyme (lactate dehydrogenase) against heat, urea and freeze-thaw treatment by compatible solute additives, J. of Molecular Catalsys B: Enzymatic, 7(104):37-45, 1999.
Gombotz et al., “Biodegradable Polymers for Protein and Peptide Drug Delivery,” Bioconjugate Chem. 6:332-351, 1995.
Gowrishankar et al., Osmoregulation in Enterobacteriaceae: Role of proline/Betaine transport systems. Current Science, 57(5): 225-234 (1988).
Green DR, “Apoptosis. Death deceiver,” Nature, 396(6712):629-630, 1998.
Green DR, “Apoptotic pathways: the roads to ruin,” Cell, 94(6):695-69, 1998.
Green et al., “Mitochondria and apoptosis,” Science, 281(5381):1309-1312, 1998.
Harding et al., Perk Is Essential for Translational Regulation and Cell Survival during the Unfolded Protein Response. (2000) Mol Cell 5:897-904. doi: 10.1016/s1097-2765(00)80330-5.
Hatam & Kayden, A High-Performance Liquid Chromatographic Method for the Determination of Tocopherol in Plasma and Cellular Elements of the Blood, Journal of Lipid Research 20:639-645 (1979).
Haze et al., Mammalian Transcription Factor ATF6 Is Synthesized as a Transmembrane Protein and Activated by Proteolysis in Response to Endoplasmic Reticulum Stress. (1999) Mol Biol Cell 10(11):3787-3799. doi: 10.1091/mbc.10.11.3787.
Henke et al., Betaine improves the PCR amplification of GC-rich DNA sequences. Nucleic Acids Research, 25(19): 3957-3958 (1997).
Hewetson et al., Sucrose concentration in blood: A new method for assessment of gastric permeability in horses with gastric ulceration. J.Vet.Inter.Med., 20:388-394, 2006.
Hoffman, “Hydrogels for biomedical applications,” Advanced Drug Delivery Reviews 43:3-12, 2002.
Holland et al., “Biological sample collection and processing for molecular epidemiological studies,” Mutation Research 543:217-234, 2003.
Holland et al., “Molecular epidemiology biomarkers—Sample collection and processing considerations,” Toxicology and Applied Pharmacology 206:261-268, 2005.
Houts et al., Reverse transcriptase from avian myeloblastosis virus. Journal of Virology, 29(2): 517-522 (1979).
Iyer et al, Enzyme stability and stabilization—Aqueous and non-aqueous environment, Process Biochemistry, 43:1019-1032 (2008).
Jin et al., Effect of mobile phase additives on resolution of some nucleic compounds in high performance liquid chromatography. Biotechnology and Bioprocess Engineering, 12:525-530, 2007.
Jones et al., “Long-term storage of DNA-free RNA for use in vaccine studies,” BioTechniques 43(5):675-681, 2007.
Kaijalainen et al., “An alternative hot start technique for PCR in small volumes using beads of wax-embedded reaction components dried in trehalose,” Nucleic Acids Research 21(12):2959-2960, 1993.
Kameda et al., “New Cyclitols, Degradation of Validamycin A By Flavobacterium Saccharophilum,” The Journal of Antibiotics 33(12):1573-1574, 1980.
Kaufman. Orchestrating the unfolded protein response in health and disease. J Clin Invest 110(10):389-1398 (2002).
Kilger and Paabo, Direct DNA sequence determination from total genomic DNA. Nucleic Acids Research, 25(10): 2032-2034 (1997).
Kim et al., Chemical Biology Investigation of Cell Death Pathways Activated by Endoplasmic Reticulum Stress Reveals Cytoprotective Modulators of ASK1. J. Biol. Chem. 284(3):1593-1603 (2009).
Kirn-Safran et al., “Heparan Sulfate Proteoglycans: Coordinators of Multiple Signaling Pathways during Chondrogenesis,” Birth Defects Research (Part C) 72:69-88, 2004.
Knapp et al., “Extrinsic protein stabilization by the naturally occurring osmolytes β-hydroxyectoine and betaine,” Extremophiles, 3:191-198, 1999.
Knuesel et al., “Comparative studies of suidatrestin, a specific inhibitor of trehalases,” Comparative Biochemistry and Physiology Part B 120:639-646, 1998.
Komiyama et al., “Hydrolysis of DNA and RNA by lanthanide ions: mechanistic studies leading to new applications,” Chem. Commun.:1443-1451, 1999.
Konishi et al., “Effects of Bay m 1099, an a-Glucosidase Inhibitor, on Starch Degradation in Germinating Mung Beans,” Biosci. Biotechnol. Biochem. 62(1):142-144, 1998.
Kotewicz et al., Isolation of closed Moloney murine leukemia virus reverse transcriptase lacking ribonuclease H activity. Nucleic Acid Research, 16(1): 265 (1988).
Kravitz, Lactate: Not guilty as charged. IDEA Fitness Journal 2(6), 23-25 (2005) http://www.unm.edu/Ikravitz/Article/%20folder/lactate.html, 3d paragraph, downloaded Jul. 31, 2014.
Kricka and Wilding, “Microchip PCR,” Anal. Bioanal. Chem 377:820-825 (2003).
Kudo et al., A molecular chaperone inducer protects neurons from ER stress. Cell Death and Differentiation, 15:364-375 (2008).
Kumar et al., “The role of proline in the prevention of aggregation during protein folding in vitro,” Biochemistry and Molecular Biology International, 46(3):509-517, 1998.
Langer. New methods of drug delivery. Science, New Series, vol. 249, No. 4976 (Sep. 28, 1990), pp. 1527-1533.
Langer, “Polymer-Controlled Drug Delivery Systems,” Acc. Chem. Res. 26:537-542, 1993.
Lawyer et al., High-level expression, purification, and enzymatic characterization of full-length Thermus aquaticus DNA polymerase and a truncated form deficient in 5′ to 3′ exonuclease activity. PCR Methods and Applications, Cold Spring Harbor Laboratory Press, 2:275-287 (1993).
Lee et al., “Analysis of the S3 and S3′ subsite specificities of feline immunodeficiency virus (FIV) protease: Development of a broad-based protease inhibitor efficacious against FIV, SW, and HIV in vitro and ex vivo,” Proc. Natl. Acad. Sci. USA 95:939-944, 1998.
Lee et al., “Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants,” J. Am. Chem. Soc. 121:1145-1155, 1999.
L-glutamine Product catalog. GlutaMAX media. Keep your cells healthier longer. Thermo Fisher Scientific Inc., 2015. Retrieved from the internet on Feb. 16, 2018, 3 pages.
Li et al., “Effect of Mobile Phase Additives on the Resolution of Four Bioactive Compounds by RP-HPLC”, Int'l Journal of Molecular Sciences, 11(5):2229-2240 (Jan. 2010).
Liao et al., “The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers,” International Journal of Pharmaceutics 304:29-39, 2005.
Loo et al., Peptide and Protein Analysis by Electrospray Ionization—MassSpectrometry and Capillary Electrophoresis-Mass Spectrometry, Anal. Biochem., 179(2):404-412 (1989).
Lou et al., “Increased amplification efficiency of microchip-based PCR by dynamic surface passivation,” Biotechniques, vol. 36, No. 2, pp. 248-252 (2004).
Lozano et al., Stabilization of x-Chymotrypsin by iconic liquids in transesterification reactions. Biotechnology and Bioengineerig, 75(5):563-569 (2001).
Luo et al., “Expression of a fusion protein of scFv-biotin mimetic peptide for immunoassay,” J. Biotechnol. 65:225, 1998.
Malin et al., “Effect of Tetrahydropyrimidine Derivatives on Protein-Nucleic Acids Interaction,” The Journal of Biological Chemistry, 274(11):6920-6929, 1999.
Manzanera et al., “Hydroxyectoine Is Superior to Trehalose for Anhydrobiotic Engineering of Pseudomanas putida KT2440,” Applied and Environmental Microbiology 68(9):4328-4333, 2002.
Manzanera et al., “Plastic Encapsulation of Stabilized Escherichia coli and Pseudomonas putida,” Applied and Environmental Microbiology 70(5):3143-3145, 2004.
Marshall et al., “NXY-059, a Free Radical-Trapping Agent, Substantially Lessens the Functional Disability Resulting From Cerebral Ischemia in a Primate Species,” Stroke, 32:190-198, 2001.
Mascellani et al., “Compatible solutes from hyperthermophiles improve the quality of DNA microarrays,” BMC Biotechnology, 7(82):1-6, 2007.
Mitchell et al., “Dispersion of Functionalized Carbon Nanotubes in Polystyrene,” Macromolecules 35:8825-8830, 2002.
Mizuguchi et al., Characterization and application to hot start PCR of neutralizing momoclonal antibodies against KOD DNA polymerase J.Biochem., 126:762-768 (1999).
Mohr, “Reversible chemical reactions as the basis for optical sensors used to detect amines, alcohols and humidity,” J. Mater. Chem., 9:2259-2264, 1999.
Mori K, Tripartite Management Mini review of Unfolded Proteins in the Endoplasmic Reticulum. Cell 101(5):451-454 (2000).
Natale et al., Sensitivity of Bovine Blastocyst Gene Expression Patterns to Culture Environments Assessed by Differential Display RT-PCR. Reproduction, 122 (5): 687-693, 2001.
New England Biolabs 1993/1994, 4 pages.
Nielsen et al., Peptide nucleic acid (PNA). A DNA mimic with a peptide backbone. Bioconjugate Chemistry, 5:3-7 (1994).
O'Brien et al. Acute sinusitis—principles of judicious use of antimicrobial agents. Pediatrics. 101 Suppl. 1: 174-177, 1998.
O'Brien et al. Cough illness/bronchitis—principles of judicious use of antimicrobial agents. Pediatrics. 101 Suppl. 1: 178-181, 1998.
Okada et al. Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. Biochem J 366(Pt 2):585-594 (2002).
Ortega et al., “New functional roles for non-collagenous domains of basement membrane collagens,” Journal of Cell Science 115:4201-4214, 2002.
Parsegian et al., “Macromolecules and Water: Probing with Osmotic Stress,” Methods in Enzymology, 259:43-94, 1995.
Pasloske et al., Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards. J Clin Microbiol.;36(12):3590-3594 (1998).
Passot et al., “Physical characterization of formulations for the development of two stable freeze-dried proteins during both dried and liquid storage,” European Journal of Pharmaceutics and Biopharmaceutics 60:335-348, 2005.
Pavlov et al., “The Role of ECM Molecules in Activity-Dependent Synaptic Development and Plasticity,” Birth Defects Research (Part C) 72:12-24, 2004.
PCT Patent Application No. PCT/US2013/077290 International Preliminary Report on Patentability mailed Jul. 2, 2015.
PCT Patent Application No. PCT/US2013/077290 International Search Report and Written Opinion mailed Jun. 23, 2014.
PCT Patent Application No. PCT/US2014/042396 International Search Report mailed Mar. 13, 2015.
PCT Patent Application No. PCT/US2014/042396 International Preliminart Report on Patentability mailed Dec. 23, 2015.
PCT Patent Application No. PCT/US2014/042396 Written Opinion mailed Mar. 13, 2015.
PCT Patent Application No. PCT/US2015/034967 International Search Report and Written Opinion dated Sep. 8, 2015.
PCT Patent Application No. PCT/US2015/034968 International Search Report and Written Opinion Mailed Sep. 16, 2015.
PCT Patent Application No. PCT/US2015/034969 International Preliminary Report on Patentability dated Dec. 22, 2016.
PCT Patent Application No. PCT/US2015/034969 International Search Report and Written Opinion dated Sep. 15, 2015.
PCT Patent Application No. PCT/US2016/065200 International Search Report and Written Opinion dated Feb. 16, 2017.
PCT Patent Appliction No. PCT/US2016/065198 International Search Report and Written Opinion dated Mar. 13, 2017.
PCT/US2005/012084 International Preliminary Report on Patentability dated Oct. 11, 2006.
PCT/US2005/012084 International Search Report dated Feb. 7, 2006.
PCT/US2006/45661 International Preliminary Report on Patentability dated Jun. 30, 2008.
PCT/US2006/45661 International Search Report and Written Opinion dated Nov. 13, 2007.
PCT/US2008/061332 International Preliminary Report on Patentability dated Oct. 27, 2009.
PCT/US2008/061332 International Search Report and Written Opinion dated Jul. 29, 2009.
PCT/US2008/068628 International Preliminary Report on Patentability dated Jan. 5, 2010.
PCT/US2008/068628 International Search Report and Written Opinion dated Aug. 27, 2009.
PCT/US2010/34454 International Preliminary Report on Patentability dated Nov. 15, 2011.
PCT/US2010/34454 International Search Report and Written Opinion dated Jan. 20, 2011.
PCT/US2011/045404 International Preliminary Report on Patentability dated Jan. 29, 2013.
PCT/US2011/045404 International Search Report and Written Opinion dated Mar. 27, 2012.
PCT/US2011/045405 International Preliminary Report on Patentability dated Jan. 29, 2013.
PCT/US2011/045405 International Search Report and Written Opinion dated Mar. 26, 2012.
PCT/US2016/065198 International Preliminary Report on Patentability dated Jun. 12, 2018.
PCTUS2016/065200 International Preliminary Report on Patentability dated Jun. 12, 2018.
PCT/US2017/058136 International Search Report and Written Opinion dated Dec. 21, 2017.
Peters et al., Sensitivity of human, murine, and rat cells to 5-Fluorouracil and 5′-Deoxy-5-fluorounidine in relation to drug-metabolozing enzymes Cancer Research, 46:20-28 (1986).
Pickering, LK, Ed. Red Book: Report of the Committee on Infectious Diseases, 26th edition. Elk Grove Village, IL, pp. 695-697, 2003.
“Polyvinyl alcohol.” Wikipedia, 6 pages, printed Oct. 17, 2017 from: https://en.wikipedia.org/wiki/Polyvinyl_alcohol.
Prestrelski et al., “Dehydration induced Conformational Transitions in Proteins and Their Inhibition by Stabilizers,” Biophysical Journal 65:661-671, 1993.
Qu et al., Ambient stable quantitative PCR reagents for the detection of Yersinia pestis. PLoS Neglected Tropical Diseases, Mar. 2010, 4(3):e629.
Roberts, “Organic compatible solutes of halotolerant and halophilic microorganisms,” Saline Systems, 1(5):1-30, 2005.
Roche. “PCR Reaction Components.” Downloaded from the internet (http://www.roche-appliedscience.com/sis/amplification/pcr_amplification_050300.html; Downloaded on Dec. 13, 2012, 4 pages.
Ron et al. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8:519-529 (2007).
Rosenstein et al. The common cold—principles of judicious use of antimicrobial agents. Pedatrics. 101 Suppl. 1: 181-184, 1998.
Sadeghi et al., Effect of alkyl chain length and temperature on the thermodynamic properties of ionic liquids 1-alkyl-3-methylimidazolium bromide in aqueous and non-aqueous solutions At different temperatures. J.Chem.Thermodynamics, 41:273-289, 2009.
Saiki et al. Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase. Science 239:487-491 (1988).
Sauer et al., “Bacterial Milking: A Novel Bioprocess for Production of Compatible Solutes,” Biotechnology and Bioengineering, 57(3):306-313, 1998.
Sawicki, “Foods high in Glutathione.” http://www.ehow.com/list_6900955_foods-high-glutathione.html, downloaded Jul. 31, 2014, 1 page.
Schnoor, et al. Characterization of the synthetic compatible solute homoectoine as a potent PCR enhancer. Biochem and Biophys. Res. Comm, 2004, 322:867-872.
Schwartz et al. Pharyngitis—principles of judicious use of antimicrobial agents. Pediatrics. 101 Suppl. 1: 171-174, 1998.
Schyma, “Erfahrungen mit der PVAL-Methode in der rechtsmedizinischen Praxis,” Arch. Kriminol. 97(1-2):41-46, 1996.
Schyma et al., “DNA-PCR Analysis of Bloodstains Samples by the Polyvinyl-Alcohol Method,” Journal of Forensic Sciences 44(1):95-99, 1999.
Schyma et al., “The Accelerated Polyvinyl-Alcohol Method for GSR Collection-PVAL 2.0,” Journal of Forensic Sciences 45(6):1303-1306, 2000.
Scouten, “A survey of enzyme coupling techniques,” Methods in Enzymology, 135:30-65, 1987.
Sigma Catalog. St. Louis:Sigma-Aldrich. p. 1987 (1998).
Sirieix-Plenet et al., “Behaviour of a binary solvent mixture constituted by an amphiphilic ionic liquid, 1-decy1-3-methylimidazolium bromide and water Potentiometric and conductimetric studies,” Talanta 63(4):979-986, Jul. 8, 2004.
Slita et al., “DNA-polycation complexes Effect of polycation structure on physico-chemical and biological properties,” Journal of Biotechnology, 127:679-693, 2007.
Smith et al., “Optimal Storage Conditions for Highly Dilute DNA Sampled: A Role for Trehalose as a Preserving Agent,” Journal of Forensic Science 50(5):1-8, 2005.
Sola-Penna et al., “Carbohydrate protection of enzyme structure and function against guanidinium chloride treatment depends on the nature of carbohydrate and enzyme,” Eur. J. Biochem., 248:24-29, 1997.
Soltis and Skalka, The alpha and beta chains of avian retrovirus reverse transcriptase independently expressed in Escherichia coli: Characterization of enzymatic activities. Proc. Nat. Acad. Sci. USA, 85:3372-3376 (1968).
Spiess et al., Trehalose is a potent PCR enhancer: Lowering of DNA melting temperature and thermal stabilization of Taq polymerase by the disaccharide trehalose. Clinical Chemistry, 2004, 50:1256-1259.
Srinivasan et al., Review—Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids, American Journal of Pathology 161(6): 1961-1971 (Dec. 2002).
Stein and Moore, The free amino acids of human blood plasma. JCB, 211:915-926, 1954.
Stock et al., Effects of ionic liquids on the acetylcholinesterase—A structure-activity relationship consideration. Green Chemistry, 6:286-290, 2004.
Suslick et al., “Colorimetric sensor arrays for molecular recognition,” Tetrahedron 60:11133-11138, 2004.
Tanriverdi et al., A rapid and automated sample-to-result HIV load test for near-patient application. Journal of Infectious Diseases, 201(S1):S52-S58, 2010.
“The dose makes the poison.” Yale chemsafe (http://learn.caim.yale.edu/chemsafe/references/dose.html, downloaded Aug. 1, 2014, 1 page.
The Frontier energy solution, Inc.'s FAQ, http://www.frontierenergysolutionsinc.com/faq/, downloaded Jul. 31, 2014.
Timasheff, “Water as Ligand: Preferential Binding and Exclusion of Denaturants in Protein Unfolding,” Biochemistry, 31(41):9857-9864, 1992.
U.S. Appl. No. 11/291,267 Office action dated Jun. 13, 2014.
U.S. Appl. No. 12/182,926 Office action dated Apr. 30, 2014.
U.S. Appl. No. 13/191,346 Office action dated Jul. 22, 2014.
U.S. Appl. No. 11/102,588 Notice of Allowance mailed Sep. 24, 2014.
U.S. Appl. No. 11/291,267 Office Action dated Mar. 12, 2015.
U.S. Appl. No. 12/509,303 Final Office action dated Jun. 9, 2014.
U.S. Appl. No. 13/191,346 Office Action dated Mar. 20, 2015.
U.S. Appl. No. 13/812,288 Restriction Requirement mailed Oct. 9, 2014.
U.S. Appl. No. 13/966,117 Final Office Action dated Feb. 26, 2015.
U.S. Appl. No. 13/966,117 Office action dated Sep. 25, 2014.
U.S. Appl. No. 13/191,346 Office Action mailed Jul. 2, 2015.
U.S. Appl. No. 13/812,288 Office Action dated Aug. 25, 2016.
U.S. Appl. No. 13/812,288 Office Action dated Feb. 1, 2017.
U.S. Appl. No. 13/812,288 Office Action dated Feb. 11, 2016.
U.S. Appl. No. 13/812,288 Office Action dated Jan. 12, 2017.
U.S. Appl. No. 13/812,288 Office Action dated May 7, 2015.
U.S. Appl. No. 14/895,475 Office Action dated Dec. 12, 2017.
U.S. Appl. No. 14/895,475 Office Action dated Jan. 10, 2017.
U.S. Appl. No. 14/895,475 Office Action dated May 22, 2017.
U.S. Appl. No. 15/164,531 dated Oct. 20, 2017.
Vanin, “Iron diethyldithiocarbamate as spin trap for nitric oxide detection,” Meth. Enzymol., 301:269-79, 1999.
Voziyan et al., “Chaperonin-assisted folding of glutamine synthetase under nonpermissive conditions: Off-pathway aggregation propensity does not determine the co-chaperonin requirement,” Protein Science, 9:2405-2412, 2000.
Wang et al., “A Naturally Occurring Protective System in Urea-Rich Cells: Mechanism of Osmolyte Protection of Proteins against Urea Denaturation,” Biochemistry, 36:9101-9108, 1997.
Wang et al., “Antibody Structure, Instability, and Formulation,” Journal of Pharmaceutical Sciences 96(1):1-26, 2007.
Wang et al., “Instability, stabilization, and formulation of liquid protein pharmaceuticals,” International Journal of Pharmaceutics 185:129-188, 1999.
Wang, “Protein aggregation and its inhibition in biopharmaceutics,” International Journal of Pharmaceutics 289:1-30, 2005.
Whitman et al., “Prokaryotes: the unseen majority,” Proc. Natl. Acad. Sci. USA, 95:6578-6583, 1998.
Whittlesey et al., “Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface,” Experimental Neurology 190:1-16, 2004.
Wierzbicka-Patynowski et al., “The ins and outs of fibronectin matrix assembly,” Journal of Cell Science 116:3269-3276, 2003.
Yamamoto et al., “Molecular Design of Bioconjugated Cell Adhesion Peptide with a Water-Soluble Polymeric Modifier for Enhancement of Antimetastatic Effect,” Current Drug Targets 3:123-130, 2002.
Yancey et al., “Living with Water Stress: Evolution of Osmolyte Systems,” Science, 217:1214-1222, 1982.
Yang et al., Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia., Exp. Neurol., 163(1):39-45, 2000.
Yoshida et al. Identification Of The cis-Acting Endoplasmic Reticulum Stress Response Element Responsible For Transcriptional Induction Of Mammalian Glucose-Regulated Proteins. J Biol Chem 273:33741-33749 (1998).
Zhang et al., Effect of Formaldehyde Treatment on the Recovery of Cell-Free Fetal DNA from Maternal Plasma at Different Processing Times, Clinica Chimica Acta 397:6-64 (2008).
Zhao et al., “NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat,” Brain Res., 909(1-2):46-50, 2001.
Zhi et al., “Renaturation of citrate synthase: Influence of denaturant and folding assistants,” Protein Science, 1:522-529, 1992.
McLean Baird et al., “Repeated Dose Study of Sucralose Tolerance in Human Subjects,” (2000) Food and Chemical Toxicology 38:2, 123-129.
Mosbah et al., Effects of Polyethylene Glycol and Hydroxyethyl Starch in University of Wisconsin Preservation Solution on Human Red Blood Cell Aggregation and Viscosity. Transplantation Proceedings. Jun. 1, 2006; 38(5):1229-35.
Extended EP Search Report for EP 23166232.1, mailed Oct. 10, 2023, 12 pages.
Related Publications (1)
Number Date Country
20210368779 A1 Dec 2021 US
Provisional Applications (1)
Number Date Country
62264786 Dec 2015 US
Continuations (2)
Number Date Country
Parent 16798522 Feb 2020 US
Child 17400931 US
Parent 15780590 US
Child 16798522 US